{"id":62875,"date":"2026-01-13T23:11:04","date_gmt":"2026-01-14T05:11:04","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=62875"},"modified":"2026-01-13T23:11:04","modified_gmt":"2026-01-14T05:11:04","slug":"trulicity-vs-ozempic-differences-benefits-and-which-to-choose","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/trulicity-vs-ozempic-differences-benefits-and-which-to-choose\/","title":{"rendered":"Trulicity vs Ozempic: Differences, Benefits and Which to Choose"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Trulicity and Ozempic are both weekly injectable GLP-1 medications, both FDA-approved for Type 2 diabetes, and both work through the same fundamental mechanism. At first glance, they seem interchangeable. But the clinical data tells a different story: Ozempic consistently outperforms Trulicity for both blood sugar control and weight loss, sometimes by a substantial margin.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The comparison matters because these medications are often presented as equivalent options, and insurance formularies or provider familiarity may steer patients toward one or the other without full consideration of the differences. If you&#8217;re choosing between them, or wondering whether to switch, understanding how they compare helps you advocate for optimal treatment.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Here&#8217;s the quick summary: Both medications effectively lower blood sugar and produce weight loss. Both have proven cardiovascular benefits. But Ozempic (semaglutide) produces approximately 15% weight loss versus 3-5% for Trulicity (dulaglutide), and HbA1c reductions are also greater with semaglutide. For most patients, Ozempic is the more effective choice. Trulicity remains a reasonable option but is generally the less potent alternative.<\/span><\/p>\n<p><b>This guide covers:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">How both medications work (same class, different molecules)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Blood sugar control: head-to-head comparison<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Weight loss effectiveness<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cardiovascular benefits<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Side effects and tolerability<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Device and administration differences<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cost and insurance considerations<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Who might choose each medication<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Switching between medications<\/span><\/li>\n<\/ul>\n<h2><b>Key Takeaways<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Both are weekly GLP-1 injections<\/b><span style=\"font-weight: 400;\"> with the same fundamental mechanism but different molecules (dulaglutide vs. semaglutide)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Ozempic produces greater weight loss<\/b><span style=\"font-weight: 400;\"> (10-15%) compared to Trulicity (3-5%)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Ozempic provides better blood sugar control,<\/b><span style=\"font-weight: 400;\"> with approximately 0.4% greater HbA1c reduction in head-to-head trials<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Both have proven cardiovascular benefits,<\/b><span style=\"font-weight: 400;\"> with similar reductions in major cardiovascular events<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Side effects are similar<\/b><span style=\"font-weight: 400;\"> since both work through GLP-1 pathways (primarily gastrointestinal)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Trulicity&#8217;s device is often considered easier to use<\/b><span style=\"font-weight: 400;\"> for patients who struggle with pen injectors<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Neither is FDA-approved specifically for weight loss;<\/b><span style=\"font-weight: 400;\"> both are approved for Type 2 diabetes<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Costs are similar<\/b><span style=\"font-weight: 400;\"> at list prices, though insurance coverage varies<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>For most patients seeking maximum benefit,<\/b><span style=\"font-weight: 400;\"> Ozempic is the superior choice<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Switching from Trulicity to Ozempic<\/b><span style=\"font-weight: 400;\"> is straightforward and commonly done<\/span><\/li>\n<\/ul>\n<h2><img decoding=\"async\" style=\"width: 100%; height: auto;\" src=\"https:\/\/i.postimg.cc\/43pFd60W\/GLP-1-Options-Compared.jpg\" alt=\"GLP-1 Options Compared\" \/><\/h2>\n<h2><b>Understanding Both Medications<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Before comparing results, understanding what these medications are and how they work provides essential context.<\/span><\/p>\n<h3><b>What Is Trulicity?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Trulicity (dulaglutide) is a GLP-1 receptor agonist manufactured by Eli Lilly:<\/span><\/p>\n<p><b>FDA approval:<\/b><span style=\"font-weight: 400;\"> 2014 for Type 2 diabetes<\/span><\/p>\n<p><b>Dosing:<\/b><span style=\"font-weight: 400;\"> Weekly subcutaneous injection (0.75mg, 1.5mg, 3.0mg, or 4.5mg)<\/span><\/p>\n<p><b>Device:<\/b><span style=\"font-weight: 400;\"> Single-use, disposable pen with hidden needle<\/span><\/p>\n<p><b>Mechanism:<\/b><span style=\"font-weight: 400;\"> Activates GLP-1 receptors to improve blood sugar control and reduce appetite<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Trulicity was one of the earlier weekly GLP-1 medications and gained popularity partly due to its user-friendly injection device.<\/span><\/p>\n<h3><b>What Is Ozempic?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Ozempic (semaglutide) is a GLP-1 receptor agonist manufactured by Novo Nordisk:<\/span><\/p>\n<p><b>FDA approval:<\/b><span style=\"font-weight: 400;\"> 2017 for Type 2 diabetes<\/span><\/p>\n<p><b>Dosing:<\/b><span style=\"font-weight: 400;\"> Weekly subcutaneous injection (0.25mg, 0.5mg, 1.0mg, or 2.0mg)<\/span><\/p>\n<p><b>Device:<\/b><span style=\"font-weight: 400;\"> Multi-dose pen requiring dose dialing<\/span><\/p>\n<p><b>Mechanism:<\/b><span style=\"font-weight: 400;\"> Activates GLP-1 receptors to improve blood sugar control and reduce appetite<\/span><\/p>\n<p><b>Related products:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Wegovy: Same semaglutide at higher dose (2.4mg), FDA-approved for weight management<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Rybelsus: Oral semaglutide for diabetes<\/span><\/li>\n<\/ul>\n<h3><b>How GLP-1 Medications Work<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Both medications work through the same pathway:<\/span><\/p>\n<p><b>Appetite reduction:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Act on brain regions controlling hunger and satiety<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Reduce appetite between meals<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Enhance feelings of fullness after eating<\/span><\/li>\n<\/ul>\n<p><b>Glucose regulation:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Stimulate insulin release when blood sugar is elevated (glucose-dependent)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Suppress glucagon release (reduces liver glucose output)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Slow gastric emptying (reduces post-meal glucose spikes)<\/span><\/li>\n<\/ul>\n<p><b>Cardiovascular effects:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Reduce inflammation<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Improve blood vessel function<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Lower blood pressure<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Reduce cardiovascular event risk<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Despite working through the same GLP-1 receptor pathway, different medications produce different effects based on their specific molecular structures and binding characteristics.<\/span><\/p>\n<h3><b>Why Results Differ<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Semaglutide and dulaglutide differ in their molecular structure, affecting potency:<\/span><\/p>\n<p><b>Semaglutide:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Modified structure for enhanced receptor binding<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Longer half-life and more stable blood levels<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Greater receptor activation at comparable doses<\/span><\/li>\n<\/ul>\n<p><b>Dulaglutide:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Linked to IgG4 antibody fragment to extend half-life<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Effective but less potent than semaglutide<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Longer track record (approved earlier)<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">These structural differences explain why semaglutide produces greater effects despite both being weekly GLP-1 medications.<\/span><\/p>\n<h2><b>Blood Sugar Control Comparison<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">For patients with Type 2 diabetes, glucose control is the primary indication for both medications.<\/span><\/p>\n<h3><b>Head-to-Head Trial: SUSTAIN 7<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">The most direct comparison comes from the SUSTAIN 7 trial, which directly compared semaglutide and dulaglutide:<\/span><\/p>\n<p><b>Study design:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">1,201 patients with Type 2 diabetes<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Compared semaglutide 0.5mg vs. dulaglutide 0.75mg<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Compared semaglutide 1.0mg vs. dulaglutide 1.5mg<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">40-week treatment duration<\/span><\/li>\n<\/ul>\n<p><b>HbA1c results:<\/b><\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Comparison<\/b><\/td>\n<td><b>Semaglutide<\/b><\/td>\n<td><b>Dulaglutide<\/b><\/td>\n<td><b>Difference<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Lower doses<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-1.5%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-1.1%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.4% advantage semaglutide<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Higher doses<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-1.8%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-1.4%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.4% advantage semaglutide<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><b>Patients achieving HbA1c &lt;7%:<\/b><\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Comparison<\/b><\/td>\n<td><b>Semaglutide<\/b><\/td>\n<td><b>Dulaglutide<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Lower doses<\/span><\/td>\n<td><span style=\"font-weight: 400;\">68%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">52%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Higher doses<\/span><\/td>\n<td><span style=\"font-weight: 400;\">79%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">67%<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Semaglutide consistently produced better glucose control at both dose comparisons.<\/span><\/p>\n<h3><b>What the Numbers Mean<\/b><\/h3>\n<p><b>0.4% HbA1c difference:<\/b><span style=\"font-weight: 400;\"> This may sound small but is clinically meaningful. Each 1% reduction in HbA1c is associated with significant reductions in diabetes complications. A 0.4% additional reduction translates to meaningfully better glucose control.<\/span><\/p>\n<p><b>More patients at target:<\/b><span style=\"font-weight: 400;\"> The higher proportion of patients reaching HbA1c &lt;7% (the standard treatment target) means more successful treatment outcomes with semaglutide.<\/span><\/p>\n<p><b>Consistent advantage:<\/b><span style=\"font-weight: 400;\"> The semaglutide advantage was consistent across both dose comparisons, suggesting it&#8217;s not simply a dosing difference but a genuine potency difference.<\/span><\/p>\n<h3><b>Fasting Glucose Comparison<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Beyond HbA1c, fasting glucose also showed differences:<\/span><\/p>\n<p><b>SUSTAIN 7 fasting glucose reduction:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Semaglutide 0.5mg: -41 mg\/dL<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Dulaglutide 0.75mg: -28 mg\/dL<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Semaglutide 1.0mg: -49 mg\/dL<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Dulaglutide 1.5mg: -35 mg\/dL<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Semaglutide produced approximately 40% greater fasting glucose reduction at comparable dose levels.<\/span><\/p>\n<h3><b>Real-World Implications<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">For diabetic patients, the blood sugar control difference matters:<\/span><\/p>\n<p><b>Reaching treatment targets:<\/b><span style=\"font-weight: 400;\"> More patients achieve their glycemic goals with semaglutide.<\/span><\/p>\n<p><b>Medication intensification:<\/b><span style=\"font-weight: 400;\"> Better control may reduce need for additional diabetes medications.<\/span><\/p>\n<p><b>Complication prevention:<\/b><span style=\"font-weight: 400;\"> Better long-term glucose control reduces risk of diabetes complications.<\/span><\/p>\n<p><b>A1c above target on Trulicity:<\/b><span style=\"font-weight: 400;\"> Patients not achieving goals on dulaglutide may benefit from switching to semaglutide.<\/span><\/p>\n<h2><b>Weight Loss Comparison<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">For many patients, weight loss is as important as blood sugar control, and this is where the medications differ most dramatically.<\/span><\/p>\n<h3><b>Head-to-Head Weight Loss: SUSTAIN 7<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">The same SUSTAIN 7 trial that showed glucose control differences also demonstrated significant weight loss differences:<\/span><\/p>\n<p><b>Weight loss results:<\/b><\/p>\n<table>\n<tbody>\n<tr>\n<td><b>Comparison<\/b><\/td>\n<td><b>Semaglutide<\/b><\/td>\n<td><b>Dulaglutide<\/b><\/td>\n<td><b>Difference<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Lower doses<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-4.6 kg (10.1 lbs)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-2.3 kg (5.1 lbs)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">2x more with semaglutide<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Higher doses<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-6.5 kg (14.3 lbs)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-3.0 kg (6.6 lbs)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">2x more with semaglutide<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Semaglutide produced approximately twice the weight loss of dulaglutide at both dose comparisons.<\/span><\/p>\n<h3><b>Percentage Weight Loss<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Expressed as percentage of body weight:<\/span><\/p>\n<p><b>Semaglutide (diabetes doses):<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Average: 4-6% weight loss at 1.0mg dose<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">At 2.0mg dose: 6-8% weight loss<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">At weight-loss doses (Wegovy 2.4mg): ~15% weight loss<\/span><\/li>\n<\/ul>\n<p><b>Dulaglutide:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Average: 2-3% weight loss at 1.5mg dose<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">At 4.5mg dose: 3-5% weight loss<\/span><\/li>\n<\/ul>\n<h3><b>Weight Loss at Maximum Doses<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Comparing maximum approved doses:<\/span><\/p>\n<p><b>Trulicity 4.5mg:<\/b><span style=\"font-weight: 400;\"> Approximately 4.5 kg (10 lbs) or 3-5% body weight<\/span><\/p>\n<p><b>Ozempic 2.0mg:<\/b><span style=\"font-weight: 400;\"> Approximately 6-8 kg (13-18 lbs) or 6-8% body weight<\/span><\/p>\n<p><b>Wegovy 2.4mg (semaglutide for weight loss):<\/b><span style=\"font-weight: 400;\"> Approximately 15% body weight<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For patients prioritizing weight loss, semaglutide offers substantially greater benefit.<\/span><\/p>\n<h3><b>What This Means Practically<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">For someone weighing 220 pounds:<\/span><\/p>\n<p><b>On Trulicity (maximum dose):<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Expected loss: 7-11 pounds<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">End weight: 209-213 pounds<\/span><\/li>\n<\/ul>\n<p><b>On Ozempic (maximum diabetes dose):<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Expected loss: 15-18 pounds<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">End weight: 202-205 pounds<\/span><\/li>\n<\/ul>\n<p><b>On Wegovy (weight loss dose):<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Expected loss: 33 pounds<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">End weight: 187 pounds<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">The difference between Trulicity and higher-dose semaglutide is substantial for patients with significant weight to lose.<\/span><\/p>\n<h3><b>Weight Loss Summary<\/b><\/h3>\n<table>\n<tbody>\n<tr>\n<td><b>Medication<\/b><\/td>\n<td><b>Average % Weight Loss<\/b><\/td>\n<td><b>Pounds Lost (220 lb start)<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Trulicity 4.5mg<\/span><\/td>\n<td><span style=\"font-weight: 400;\">3-5%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">7-11 lbs<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Ozempic 2.0mg<\/span><\/td>\n<td><span style=\"font-weight: 400;\">6-8%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">13-18 lbs<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Wegovy 2.4mg<\/span><\/td>\n<td><span style=\"font-weight: 400;\">15%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">33 lbs<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><b>Cardiovascular Benefits<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Both medications have proven cardiovascular benefits, which is important given the high cardiovascular risk in patients with Type 2 diabetes.<\/span><\/p>\n<h3><b>Trulicity Cardiovascular Data (REWIND Trial)<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">The REWIND trial studied dulaglutide in patients with Type 2 diabetes:<\/span><\/p>\n<p><b>Study population:<\/b><span style=\"font-weight: 400;\"> 9,901 patients with Type 2 diabetes, broader population including those without prior cardiovascular events<\/span><\/p>\n<p><b>Results:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">12% reduction in major adverse cardiovascular events (MACE)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Statistically significant cardiovascular protection<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Benefit seen in both primary and secondary prevention<\/span><\/li>\n<\/ul>\n<h3><b>Ozempic Cardiovascular Data (SUSTAIN 6 and SELECT)<\/b><\/h3>\n<p><b>SUSTAIN 6 trial (diabetes population):<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">26% reduction in MACE in patients with Type 2 diabetes and high cardiovascular risk<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Significant cardiovascular protection<\/span><\/li>\n<\/ul>\n<p><b>SELECT trial (obesity population):<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">20% reduction in MACE in patients with obesity and established cardiovascular disease<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Studied for cardiovascular outcomes regardless of diabetes status<\/span><\/li>\n<\/ul>\n<h3><b>Cardiovascular Comparison<\/b><\/h3>\n<table>\n<tbody>\n<tr>\n<td><b>Factor<\/b><\/td>\n<td><b>Trulicity (REWIND)<\/b><\/td>\n<td><b>Ozempic (SUSTAIN 6)<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">MACE reduction<\/span><\/td>\n<td><span style=\"font-weight: 400;\">12%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">26%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Population studied<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Broader diabetes population<\/span><\/td>\n<td><span style=\"font-weight: 400;\">High-risk diabetes population<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Statistical significance<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Yes<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Yes<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Both medications provide cardiovascular protection. The trials studied somewhat different populations, making direct comparison imperfect. However, semaglutide&#8217;s 26% reduction versus dulaglutide&#8217;s 12% reduction suggests potentially greater cardiovascular benefit, though the different study populations warrant caution in direct comparison.<\/span><\/p>\n<h3><b>Cardiovascular Bottom Line<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Both Trulicity and Ozempic provide proven cardiovascular protection, making them preferred options for diabetic patients with cardiovascular disease or risk factors. Either is substantially better than diabetes medications without cardiovascular benefit.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For patients where cardiovascular protection is the primary concern, both are reasonable choices, though semaglutide&#8217;s data may suggest greater benefit.<\/span><\/p>\n<h2><b>Side Effect Comparison<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Since both medications work through the same GLP-1 pathway, their side effect profiles are similar.<\/span><\/p>\n<h3><b>Common Side Effects<\/b><\/h3>\n<p><b>Trulicity common side effects:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Nausea (12-21%)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Diarrhea (8-12%)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Vomiting (6-12%)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Abdominal pain (7-10%)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Decreased appetite (5-9%)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Indigestion (5-8%)<\/span><\/li>\n<\/ul>\n<p><b>Ozempic common side effects:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Nausea (15-20%)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Vomiting (5-10%)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Diarrhea (8-10%)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Abdominal pain (6-8%)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Constipation (3-5%)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Decreased appetite (intended effect)<\/span><\/li>\n<\/ul>\n<h3><b>Side Effect Comparison Table<\/b><\/h3>\n<table>\n<tbody>\n<tr>\n<td><b>Side Effect<\/b><\/td>\n<td><b>Trulicity<\/b><\/td>\n<td><b>Ozempic<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Nausea<\/span><\/td>\n<td><span style=\"font-weight: 400;\">12-21%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">15-20%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Diarrhea<\/span><\/td>\n<td><span style=\"font-weight: 400;\">8-12%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">8-10%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Vomiting<\/span><\/td>\n<td><span style=\"font-weight: 400;\">6-12%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">5-10%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Abdominal pain<\/span><\/td>\n<td><span style=\"font-weight: 400;\">7-10%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">6-8%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Constipation<\/span><\/td>\n<td><span style=\"font-weight: 400;\">4-7%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">3-5%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Injection site reactions<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.5-2%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.2-1%<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">The rates are broadly similar, with individual variation determining which medication a particular patient tolerates better.<\/span><\/p>\n<h3><b>Serious Risks<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Both medications carry similar rare but serious risks:<\/span><\/p>\n<p><b>Pancreatitis:<\/b><span style=\"font-weight: 400;\"> Can occur with either medication. Severe abdominal pain requires immediate medical attention.<\/span><\/p>\n<p><b>Gallbladder disease:<\/b><span style=\"font-weight: 400;\"> Weight loss increases gallstone risk. Both medications can contribute.<\/span><\/p>\n<p><b>Thyroid concerns:<\/b><span style=\"font-weight: 400;\"> Animal studies showed thyroid tumors with both medications. Human risk is uncertain. Both are contraindicated with personal\/family history of medullary thyroid carcinoma or MEN2.<\/span><\/p>\n<p><b>Hypoglycemia:<\/b><span style=\"font-weight: 400;\"> Low risk with either medication alone. Risk increases if combined with insulin or sulfonylureas.<\/span><\/p>\n<h3><b>Tolerability Differences<\/b><\/h3>\n<p><b>Potential Trulicity advantage:<\/b><span style=\"font-weight: 400;\"> Some patients report fewer GI effects, possibly due to different formulation or dosing patterns. Trulicity&#8217;s device may reduce injection-related anxiety.<\/span><\/p>\n<p><b>Potential Ozempic advantage:<\/b><span style=\"font-weight: 400;\"> The gradual titration schedule may help patients adjust more smoothly. Lower starting doses (0.25mg) allow gentler introduction.<\/span><\/p>\n<p><b>Overall:<\/b><span style=\"font-weight: 400;\"> Most patients tolerate both medications reasonably well with proper titration. Neither has a clear tolerability advantage for the majority of patients.<\/span><\/p>\n<h3><b>Discontinuation Rates<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Clinical trial discontinuation rates due to adverse events are similar:<\/span><\/p>\n<p><b>Trulicity:<\/b><span style=\"font-weight: 400;\"> 5-8% discontinuation due to adverse events<\/span><\/p>\n<p><b>Ozempic:<\/b><span style=\"font-weight: 400;\"> 5-7% discontinuation due to adverse events<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Neither medication has a significant dropout advantage.<\/span><\/p>\n<h2><b>Device and Administration<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">One area where Trulicity has historically been considered advantageous is its injection device.<\/span><\/p>\n<h3><b>Trulicity Device<\/b><\/h3>\n<p><b>Design features:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Single-use, pre-filled pen<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Hidden needle (never seen by patient)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">One-button activation<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Automatic injection process<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">No dose dialing required<\/span><\/li>\n<\/ul>\n<p><b>User experience:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Often described as very easy to use<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Good for needle-phobic patients<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Minimal steps: attach, press, hold<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Automatic needle insertion and retraction<\/span><\/li>\n<\/ul>\n<p><b>Potential limitations:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Fixed dose per pen (less flexibility)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">More waste (entire device discarded)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Must match prescription to available pen strengths<\/span><\/li>\n<\/ul>\n<h3><b>Ozempic Device<\/b><\/h3>\n<p><b>Design features:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Multi-dose pen (typically 4-week supply)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Requires attaching needle<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Dose must be dialed<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Manual injection process<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Visible needle (though small)<\/span><\/li>\n<\/ul>\n<p><b>User experience:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">More steps required than Trulicity<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Requires dose selection<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Needle attachment needed<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">More typical of traditional insulin pens<\/span><\/li>\n<\/ul>\n<p><b>Potential advantages:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">More flexible dosing<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Less packaging waste<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">May be easier to verify dose delivery<\/span><\/li>\n<\/ul>\n<h3><b>Device Comparison<\/b><\/h3>\n<table>\n<tbody>\n<tr>\n<td><b>Factor<\/b><\/td>\n<td><b>Trulicity<\/b><\/td>\n<td><b>Ozempic<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Needle visibility<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Hidden<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Visible (small)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Dose dialing<\/span><\/td>\n<td><span style=\"font-weight: 400;\">No (preset)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Yes<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Needle attachment<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Pre-attached<\/span><\/td>\n<td><span style=\"font-weight: 400;\">User attaches<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Steps to inject<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Fewer<\/span><\/td>\n<td><span style=\"font-weight: 400;\">More<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Dose flexibility<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Fixed pen doses<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Dial any dose<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Waste<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Higher (single use)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Lower (multi-dose)<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><b>Does Device Matter?<\/b><\/h3>\n<p><b>For some patients, yes:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Needle-phobic patients may strongly prefer Trulicity&#8217;s hidden needle<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Patients with dexterity issues may find Trulicity&#8217;s simpler operation easier<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Some find the one-button process less intimidating<\/span><\/li>\n<\/ul>\n<p><b>For most patients, not significantly:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Both devices are manageable with brief instruction<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Most patients adapt to either device quickly<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Device preference rarely outweighs efficacy differences<\/span><\/li>\n<\/ul>\n<p><b>The bottom line:<\/b><span style=\"font-weight: 400;\"> Device preference shouldn&#8217;t typically override the substantial efficacy difference between medications. Both devices work well for most patients with minimal practice.<\/span><\/p>\n<h2><b>Cost and Insurance<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Cost considerations can influence medication choice, particularly when insurance coverage differs.<\/span><\/p>\n<h3><b>List Prices<\/b><\/h3>\n<p><b>Trulicity:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">List price: ~$900-1,000\/month<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Available doses: 0.75mg, 1.5mg, 3.0mg, 4.5mg<\/span><\/li>\n<\/ul>\n<p><b>Ozempic:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">List price: ~$900-1,000\/month<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Available doses: 0.25mg, 0.5mg, 1.0mg, 2.0mg<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">List prices are essentially equivalent.<\/span><\/p>\n<h3><b>Manufacturer Programs<\/b><\/h3>\n<p><b>Trulicity (Eli Lilly):<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Savings card programs available for commercially insured patients<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">May reduce cost to $25-100\/month for eligible patients<\/span><\/li>\n<\/ul>\n<p><b>Ozempic (Novo Nordisk):<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">NovoCare savings programs<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cash-pay program: $349\/month without insurance<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">May reduce cost to $25-100\/month for eligible patients<\/span><\/li>\n<\/ul>\n<h3><b>Compounded Options<\/b><\/h3>\n<p><b>Trulicity:<\/b><span style=\"font-weight: 400;\"> No compounded version available (proprietary formulation)<\/span><\/p>\n<p><b>Semaglutide:<\/b><span style=\"font-weight: 400;\"> Compounded versions available<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">TrimRx: $199\/month for compounded semaglutide<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Contains same active ingredient<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">The availability of compounded semaglutide provides a cost advantage not available with dulaglutide.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For detailed pricing, see our guide on <\/span><a href=\"https:\/\/trimrx.com\/blog\/compounded-semaglutide-complete-cost-and-safety-guide\/\"><span style=\"font-weight: 400;\">compounded semaglutide costs<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<h3><b>Insurance Coverage<\/b><\/h3>\n<p><b>Trulicity:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Often on diabetes medication formularies<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">May be preferred due to established relationships with Eli Lilly<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Prior authorization typically required<\/span><\/li>\n<\/ul>\n<p><b>Ozempic:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Also commonly covered for diabetes<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">May face step therapy requirements<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Prior authorization typically required<\/span><\/li>\n<\/ul>\n<p><b>Coverage varies by plan:<\/b><span style=\"font-weight: 400;\"> Some plans prefer one medication over the other based on rebate agreements. Your specific formulary determines which is more accessible.<\/span><\/p>\n<h3><b>Cost Comparison Summary<\/b><\/h3>\n<table>\n<tbody>\n<tr>\n<td><b>Factor<\/b><\/td>\n<td><b>Trulicity<\/b><\/td>\n<td><b>Ozempic\/Semaglutide<\/b><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">List price<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~$950\/month<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~$950\/month<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Best manufacturer price<\/span><\/td>\n<td><span style=\"font-weight: 400;\">~$25-100\/month<\/span><\/td>\n<td><span style=\"font-weight: 400;\">$349\/month (cash-pay)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Compounded option<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Not available<\/span><\/td>\n<td><span style=\"font-weight: 400;\">$199\/month<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Insurance coverage<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Variable<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Variable<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">The availability of compounded semaglutide provides an access option that doesn&#8217;t exist for dulaglutide, potentially making semaglutide more accessible for patients without insurance coverage.<\/span><\/p>\n<h2><b>Who Should Choose Each Medication?<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Despite Ozempic&#8217;s advantages, certain situations might favor Trulicity.<\/span><\/p>\n<h3><b>Reasons to Consider Trulicity<\/b><\/h3>\n<p><b>Insurance\/formulary requirements:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Your insurance covers Trulicity but not Ozempic<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Step therapy requires trying Trulicity first<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Formulary preference makes Trulicity significantly less expensive<\/span><\/li>\n<\/ul>\n<p><b>Device preference:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Strong needle phobia that Trulicity&#8217;s hidden needle addresses<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Significant dexterity limitations making Trulicity&#8217;s device easier<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Preference for simpler device operation<\/span><\/li>\n<\/ul>\n<p><b>Provider familiarity:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Your provider is more experienced with Trulicity<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Established care relationship involves Trulicity<\/span><\/li>\n<\/ul>\n<p><b>Previous experience:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Known tolerance of dulaglutide<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Previous success with Trulicity<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Concerns about switching established treatment<\/span><\/li>\n<\/ul>\n<p><b>Specific circumstances:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Part of a comprehensive treatment plan designed around dulaglutide<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Provider has specific clinical reasons to prefer dulaglutide<\/span><\/li>\n<\/ul>\n<h3><b>Reasons Ozempic Is Usually Better<\/b><\/h3>\n<p><b>Greater effectiveness:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Approximately 0.4% better HbA1c reduction<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Approximately twice the weight loss<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Higher proportion of patients reaching treatment targets<\/span><\/li>\n<\/ul>\n<p><b>Weight loss priority:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Significant weight to lose<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Metabolic benefits of weight loss important<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Weight-related health conditions (sleep apnea, joint pain, etc.)<\/span><\/li>\n<\/ul>\n<p><b>Cardiovascular considerations:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Potentially greater cardiovascular protection (26% vs. 12% event reduction)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">High cardiovascular risk where maximum protection matters<\/span><\/li>\n<\/ul>\n<p><b>Access to higher doses:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Wegovy (semaglutide 2.4mg) available for weight management<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Maximum Ozempic dose (2.0mg) produces more weight loss than maximum Trulicity dose (4.5mg)<\/span><\/li>\n<\/ul>\n<p><b>Compounded option:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Budget constraints where compounded semaglutide ($199\/month) provides access<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Insurance doesn&#8217;t cover either and cash-pay needed<\/span><\/li>\n<\/ul>\n<h3><b>The General Recommendation<\/b><\/h3>\n<p><b>For most patients:<\/b><span style=\"font-weight: 400;\"> Ozempic (semaglutide) is the preferred choice due to:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Superior glucose control<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Substantially greater weight loss<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Potentially stronger cardiovascular protection<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Equivalent convenience (both weekly)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Availability of compounded option for cost-conscious patients<\/span><\/li>\n<\/ul>\n<p><b>Trulicity remains reasonable:<\/b><span style=\"font-weight: 400;\"> When insurance strongly favors it, device preference is compelling, or specific circumstances warrant, but it&#8217;s generally the less effective option.<\/span><\/p>\n<h2><b>Switching Between Medications<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Many patients consider switching from Trulicity to Ozempic, and this is commonly done.<\/span><\/p>\n<h3><b>Why Patients Switch<\/b><\/h3>\n<p><b>Common reasons to switch from Trulicity to Ozempic:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Inadequate blood sugar control despite maximum Trulicity dose<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Desire for greater weight loss<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Wanting to try the more potent option<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Insurance change favoring Ozempic<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Access to compounded semaglutide<\/span><\/li>\n<\/ul>\n<p><b>Common reasons to switch from Ozempic to Trulicity:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Insurance change favoring Trulicity<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Intolerable side effects on Ozempic (trying alternative)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Device preference<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Provider recommendation<\/span><\/li>\n<\/ul>\n<h3><b>How to Switch<\/b><\/h3>\n<p><b>From Trulicity to Ozempic:<\/b><\/p>\n<ol>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Stop Trulicity (no taper needed)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Begin Ozempic at starting dose (0.25mg)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Follow standard titration schedule<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Can start Ozempic the week after last Trulicity dose<\/span><\/li>\n<\/ol>\n<p><b>From Ozempic to Trulicity:<\/b><\/p>\n<ol>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Stop Ozempic (no taper needed)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Begin Trulicity at appropriate dose<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Provider may start at maintenance dose given GLP-1 experience<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Can start Trulicity the week after last Ozempic dose<\/span><\/li>\n<\/ol>\n<h3><b>What to Expect When Switching<\/b><\/h3>\n<p><b>Transitioning to Ozempic:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">GI side effects may recur during titration even if tolerating Trulicity<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Full Ozempic effect takes several weeks to months (titration period)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Greater appetite suppression and potential weight loss as reaching higher doses<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Some providers use accelerated titration for patients switching from other GLP-1s<\/span><\/li>\n<\/ul>\n<p><b>Transitioning to Trulicity:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Similar GI adjustment period possible<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">May notice less appetite suppression compared to Ozempic<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Blood sugar may change during transition; monitor closely<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Weight may stabilize or increase compared to Ozempic trajectory<\/span><\/li>\n<\/ul>\n<h3><b>Provider Involvement<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Switching between GLP-1 medications should involve your healthcare provider:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Appropriate dosing decisions<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Timing of transition<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Monitoring blood sugar during switch<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Adjustment of any concurrent diabetes medications<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Follow-up to assess response to new medication<\/span><\/li>\n<\/ul>\n<h2><b>Special Populations<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Certain patient groups may have specific considerations when choosing between these medications.<\/span><\/p>\n<h3><b>Patients With Type 2 Diabetes<\/b><\/h3>\n<p><b>Both medications are appropriate<\/b><span style=\"font-weight: 400;\"> as they&#8217;re specifically approved for diabetes.<\/span><\/p>\n<p><b>Ozempic advantage:<\/b><span style=\"font-weight: 400;\"> Better glucose control and more patients reaching HbA1c targets.<\/span><\/p>\n<p><b>Consider:<\/b><span style=\"font-weight: 400;\"> If blood sugar is well-controlled on Trulicity, switching may not be necessary. If targets aren&#8217;t being met, Ozempic may help.<\/span><\/p>\n<h3><b>Patients With Obesity and Diabetes<\/b><\/h3>\n<p><b>Ozempic\/Wegovy advantage:<\/b><span style=\"font-weight: 400;\"> Substantially greater weight loss makes semaglutide preferred for patients where weight is a significant concern alongside diabetes.<\/span><\/p>\n<p><b>Access consideration:<\/b><span style=\"font-weight: 400;\"> Wegovy (weight loss indication) may have different coverage than Ozempic (diabetes indication).<\/span><\/p>\n<h3><b>Patients With Cardiovascular Disease<\/b><\/h3>\n<p><b>Both are appropriate<\/b><span style=\"font-weight: 400;\"> with proven cardiovascular protection.<\/span><\/p>\n<p><b>Potential Ozempic advantage:<\/b><span style=\"font-weight: 400;\"> Larger cardiovascular event reduction in SUSTAIN 6 (26%) versus REWIND (12%), though study populations differed.<\/span><\/p>\n<p><b>Either acceptable:<\/b><span style=\"font-weight: 400;\"> For patients where cardiovascular protection is the primary goal, both provide meaningful benefit.<\/span><\/p>\n<h3><b>Patients New to GLP-1 Medications<\/b><\/h3>\n<p><b>For treatment-naive patients:<\/b><span style=\"font-weight: 400;\"> Starting with the more effective option (Ozempic) makes sense unless specific circumstances favor Trulicity.<\/span><\/p>\n<p><b>No need to try Trulicity first:<\/b><span style=\"font-weight: 400;\"> Unless insurance requires step therapy, there&#8217;s no clinical rationale to start with the less effective medication.<\/span><\/p>\n<h3><b>Patients on Trulicity With Suboptimal Results<\/b><\/h3>\n<p><b>Consider switching to Ozempic:<\/b><span style=\"font-weight: 400;\"> If blood sugar or weight aren&#8217;t adequately controlled on Trulicity, semaglutide may produce better results.<\/span><\/p>\n<p><b>Assess adherence first:<\/b><span style=\"font-weight: 400;\"> Ensure suboptimal results aren&#8217;t due to missed doses or other factors before switching.<\/span><\/p>\n<h2><b>Frequently Asked Questions<\/b><\/h2>\n<p><b>Which medication is more effective for blood sugar control, Trulicity or Ozempic?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Ozempic (semaglutide) is more effective for blood sugar control. In the head-to-head SUSTAIN 7 trial, semaglutide produced approximately 0.4% greater HbA1c reduction than dulaglutide at comparable doses. More patients achieved the target HbA1c of less than 7% with semaglutide (79% versus 67% at higher doses). Fasting glucose reduction was also approximately 40% greater with semaglutide. While both medications effectively lower blood sugar, semaglutide consistently provides better glycemic control.<\/span><\/p>\n<p><b>Which medication produces more weight loss, Trulicity or Ozempic?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Ozempic produces substantially more weight loss. In the SUSTAIN 7 trial, semaglutide produced approximately twice the weight loss of dulaglutide at comparable doses. At maximum doses, Trulicity produces approximately 3-5% body weight loss, while Ozempic produces 6-8%, and Wegovy (higher-dose semaglutide) produces approximately 15%. For a 220-pound person, this translates to roughly 7-11 pounds lost on Trulicity versus 15-18 pounds on Ozempic, or 33 pounds on Wegovy. For patients prioritizing weight loss, semaglutide is clearly superior.<\/span><\/p>\n<p><b>Are the side effects the same for both medications?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">The side effects are very similar since both work through the same GLP-1 pathway. Both primarily cause gastrointestinal effects: nausea, diarrhea, vomiting, abdominal pain, and constipation. Rates are broadly comparable, typically affecting 10-20% of patients. Both carry the same rare serious risks: pancreatitis, gallbladder disease, and theoretical thyroid tumor concerns. Neither has a clear tolerability advantage for most patients. Individual response varies, and some patients may tolerate one better than the other, but this can only be determined by trying the medications.<\/span><\/p>\n<p><b>Is Trulicity&#8217;s injection device easier to use than Ozempic&#8217;s?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Many patients find Trulicity&#8217;s device easier to use because it features a hidden needle (addressing needle phobia), requires no dose dialing (pre-set doses), and operates with a simple one-button press. Ozempic requires attaching a needle, dialing the dose, and a more traditional injection process. For needle-phobic patients or those with dexterity issues, Trulicity&#8217;s device may be advantageous. However, most patients adapt to either device quickly with brief instruction, and device preference typically shouldn&#8217;t override the significant efficacy differences between medications.<\/span><\/p>\n<p><b>Can I switch from Trulicity to Ozempic?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Yes, switching from Trulicity to Ozempic is straightforward and commonly done. You would stop Trulicity and begin Ozempic at its starting dose (0.25mg), following the standard titration schedule. There&#8217;s no mandatory waiting period between medications. Many patients switch to achieve better blood sugar control or greater weight loss. Expect some GI side effect adjustment during Ozempic titration even if you tolerated Trulicity well. Full benefit of the switch develops over several weeks to months as you reach maintenance doses. Your healthcare provider should guide the transition.<\/span><\/p>\n<p><b>Do both medications provide cardiovascular protection?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Yes, both Trulicity and Ozempic have demonstrated cardiovascular protection in large outcome trials. The REWIND trial showed Trulicity reduces major adverse cardiovascular events by 12% in patients with Type 2 diabetes. The SUSTAIN 6 trial showed Ozempic reduces these events by 26% in high-risk diabetic patients. Both medications are preferred options for diabetic patients with or at risk for cardiovascular disease. While Ozempic&#8217;s reduction appears larger, the trials studied somewhat different populations, making direct comparison imperfect. Either medication provides meaningful cardiovascular benefit.<\/span><\/p>\n<p><b>Which medication is cheaper, Trulicity or Ozempic?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">List prices are essentially equivalent (approximately $900-1,000\/month for either). With manufacturer savings programs, both can be reduced to $25-100\/month for eligible commercially insured patients. The key cost difference is that compounded semaglutide is available ($199\/month through TrimRx), while no compounded dulaglutide exists. For patients paying cash or without insurance coverage for either medication, compounded semaglutide provides an access option that Trulicity cannot match. Insurance formulary preferences vary by plan and may favor one medication over the other.<\/span><\/p>\n<p><b>Is Trulicity FDA-approved for weight loss?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">No, Trulicity is FDA-approved only for Type 2 diabetes, not weight loss. Any weight loss is considered a secondary benefit, not the primary indication. Similarly, Ozempic is approved for diabetes, not weight loss. However, Wegovy (the same semaglutide at higher doses) is FDA-approved specifically for chronic weight management. For patients seeking weight loss treatment, semaglutide offers the advantage of having both diabetes (Ozempic) and weight loss (Wegovy) formulations, plus compounded options for weight loss.<\/span><\/p>\n<p><b>Should I try Trulicity before Ozempic?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Unless your insurance requires step therapy (trying one medication before another), there&#8217;s no clinical rationale to try Trulicity first. Since Ozempic is more effective for both blood sugar control and weight loss, starting with the more effective option makes sense for most patients. Some insurance plans do require trying dulaglutide or other medications before approving semaglutide, which would be a practical reason to start with Trulicity. But from a purely clinical standpoint, semaglutide is typically the better first choice.<\/span><\/p>\n<p><b>If I&#8217;m doing well on Trulicity, should I switch to Ozempic?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">This depends on your treatment goals and current results. If your blood sugar is at target, you&#8217;re satisfied with your weight, and you&#8217;re tolerating Trulicity well, there may be no compelling reason to switch. However, if you&#8217;re not achieving optimal blood sugar control, would like to lose more weight, or want to see if you can do better, switching to Ozempic may produce improved results. The decision should involve your healthcare provider, considering your individual circumstances, goals, and preferences.<\/span><\/p>\n<p><b>Can I take either medication if I have heart disease?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Yes, both Trulicity and Ozempic are appropriate and even preferred for patients with Type 2 diabetes and cardiovascular disease. Both have demonstrated cardiovascular protection in clinical trials. Guidelines recommend GLP-1 medications with proven cardiovascular benefit for diabetic patients with or at high risk for cardiovascular disease. Either medication is a good choice for this population, though Ozempic&#8217;s potentially greater cardiovascular protection (26% versus 12% event reduction) may make it slightly preferable for patients where cardiovascular risk is the primary concern.<\/span><\/p>\n<h2><b>The Bottom Line<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Trulicity and Ozempic are both weekly GLP-1 medications for Type 2 diabetes, but they are not equivalent. Ozempic consistently outperforms Trulicity across key outcomes: approximately 0.4% better HbA1c reduction, roughly twice the weight loss, and potentially greater cardiovascular protection. The side effect profiles are similar, and while Trulicity has a more user-friendly device, this advantage rarely outweighs the significant efficacy differences.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For most patients, Ozempic is the better choice. The greater effectiveness in both glucose control and weight loss, combined with the availability of compounded semaglutide for cost-conscious patients, makes semaglutide the preferred option.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Trulicity remains a reasonable medication when insurance strongly favors it, device preference is compelling, or specific circumstances warrant. But when choosing between these medications based on clinical merit alone, semaglutide is the superior option for most patients.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Ready to explore semaglutide treatment? <\/span><a href=\"https:\/\/trimrx.com\/product\/semaglutide\"><span style=\"font-weight: 400;\">TrimRx offers consultations with licensed providers<\/span><\/a><span style=\"font-weight: 400;\"> who can evaluate your eligibility and prescribe compounded semaglutide at $199\/month for qualifying patients.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Trulicity and Ozempic are both weekly injectable GLP-1 medications, both FDA-approved for Type 2 diabetes, and both work through the same fundamental mechanism. At&#8230;<\/p>\n","protected":false},"author":7,"featured_media":51758,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[8],"tags":[],"class_list":["post-62875","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ozempic"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/62875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=62875"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/62875\/revisions"}],"predecessor-version":[{"id":62876,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/62875\/revisions\/62876"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/51758"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=62875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=62875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=62875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}